PADs介导的瓜氨酸化与肿瘤关系的研究进展

瓜氨酸化(citrullination)是指在蛋白质精氨酸脱亚胺酶(peptidylarginine deiminases,PADs)作用下蛋白质肽链中的精氨酸残基转化为瓜氨酸残基的过程,是一种重要的蛋白质翻译后修饰的过程。目前,已有5种PAD酶在人体组织中被发现,分别为PAD1~4和PAD6,PAD2和PAD4在许多恶性肿瘤组织中呈高表达。研究发现组蛋白、细胞角蛋白、纤维粘连蛋白、白介素8等蛋白质均可被瓜氨酸化,并与肿瘤细胞的增殖、分化、凋亡、迁移等密切相关。本文从表观遗传学观点出发就PADs介导的蛋白质瓜氨酸化与肿瘤关系的研究进展进行综述,为深入探讨肿瘤的发生发展机制及其治疗提供新的研究思路。     

肽基精氨酸脱亚胺酶4(PADI4)对RA的影响

类风湿关节炎(RA)是一种病因和发病机制尚不清楚的自身免疫疾病,一般认为是由多种遗传因素和环境因素共同作用的结果。遗传因素中以组织相容性白细胞抗原HLA最为重要,另外作为非HLA的肽基精氨酸脱亚胺酶4(PADI4)也参与了RA的发病。PADI4是一种翻译后修饰酶,可在钙离子存在的情况下将精氨酸残基转化为瓜氨酸残基,瓜氨酸化后的蛋白质往往改变其分子构象,从而导致其生化活性亦发生改变。在不用种族的人群中,PADI4基因多态性与RA的易感性不尽相同。PADI4在RA患者血清中含量明显升高,在机体内产生自身抗PADI4抗体,并且PADI4瓜氨酸化多种蛋白质引起机体自身的免疫反应参与RA的发生与发展。近些年来的其他研究表明PAID4也参与了肿瘤、溃疡性结肠炎、多发性硬化症的发病。尽管针对PADI4的研究已经取得了很多重大进展,但是仍然存在很多悬而未决的问题等待科研工作者进一步的研究和证实。     

肽酰精氨酸的翻译后修饰

肽酰精氨酸残基甲基化作用是细胞质与细胞核内蛋白质翻译后修饰的普遍方式。精氨酸残基甲基化蛋白质与许多细胞生物学过程有关,包括转录调节、RNA代谢和DNA损伤修复等。生物体内精氨酸N-甲基转移酶类、肽酰精氨酸脱亚氨酶类与JMJD6等催化肽酰精氨酸残基进行甲基化、瓜氨酸化和去甲基化的动态修饰。这种动态修饰对细胞生物学功能有重要调节作用。     

PAD4参与中性粒细胞胞外诱捕网的抗菌作用

蛋白质精氨酸脱亚氨酶4(PAD4)是中性粒细胞胞外诱捕网(NET)介导的细菌杀灭途径中的重要免疫因子。PAD4催化组蛋白瓜氨酸化,促进细菌感染期中性粒细胞形成NET。PAD4/中性粒细胞在炎性因子或细菌作用下不能形成NET,PAD4/鼠相对于PAD4+/+鼠更易受细菌感染。     

保守的第52位色氨酸突变引起的胰高血糖素样肽1受体N端片段活性丧失

通过易错PCR方法建立了一个鼠肺不同长度的nGLP-1R(从第21个氨基酸开始到第145个氨基酸)的噬菌体随机突变展示肽库,通过噬菌体表面展示技术检测胰高血糖素样肽1受体N端片段(nGLP-1R)在缺失一段或两段基因后是否还具有结合Exendin-4的活性.经ELISA分析发现了一株无结合活性的突变株,命名为EP16.经测序比对,发现EP16缺失了前20个和后10个氨基酸,且第52位色氨酸突变为精氨酸.为确定EP16与Exendin-4无结合活性的原因,重新构建了无前20个和后10个氨基酸的EP16野生型及第52位色氨酸变为精氨酸的全长nGLP-1Rw52R与EP16进行对比分析.结果表明,EP16的活性丧失是由保守的第52位色氨酸突变为精氨酸引起的,缺失的前20个和后10个氨基酸没有影响其生物学活性.关键位点单个氨基酸残基的突变可以改变胰高血糖素样肽1受体N端片段整个蛋白质的生物学活性.     

类ACE抑制肽的合成及其活性分析

血管紧张素转换酶(angiotensin converting enzyme,ACE)通过作用于维持血压正常的肾素-血管紧张系统(rennin-angiotensin system, RAS)和激肽释放酶 激肽系统(kallikrein-kinin system, KKS),使其失衡导致血压升高．而ACE活性抑制肽可以竞争性地与ACE的活性中心结合,从而抑制ACE的活性,使血压降低．天然来源的ACE抑制肽与传统的降压药物相比效果较好,无毒副作用,对正常血压没有影响,对于高血压的治疗和人类健康具有重要意义. 本文以酪蛋白中提取的ACE活性抑制肽KVLPVP为先导肽,根据ACE抑制肽的结构特点,设计合成一系列的类ACE肽(similar ACE-like peptides). 利用反相高效液相色谱法(RP-HPLC)直接测定其体外ACE抑制活性. 结果表明,当芳香性的氨基酸残基Phe、Tyr、His和疏水性Val残基位于C-端时会提高多肽的ACE抑制活性,尤其是His位于C 端时,ACE抑制活性更强. 通过对比先导肽与所合成的类ACE肽的ACE活性抑制率,可以发现,类ACE肽的ACE活性抑制率均高于先导肽．基于不同氨基酸残基位于C-端时对多肽的ACE抑制活性的研究,可以为降血压药物分子设计和筛选提供基础.     

棉铃虫可溶型海藻糖酶的化学修饰

【目的】本研究旨在通过分析化学修饰剂对棉铃虫Helicoverpa armigera可溶型海藻糖酶活性的影响,以明确海藻糖酶活性中心的结构特点和氨基酸构成。【方法】采用化学修饰方法,测定不同修饰剂处理后棉铃虫5龄幼虫海藻糖酶催化活性的变化,进而通过化学修饰反应失活常数来推测酶活性中心的特定氨基酸残基数量。【结果】采用8 mmol/L水溶性碳二亚胺(carbodiimide,EDC)溶液和25 mmol/L苯甲酰甲醛(phenylglyoxal,PG)溶液分别对棉铃虫5龄幼虫海藻糖酶羧酸基团和精氨酸残基进行修饰后,其活性分别减少81.58%和54.14%,这表明对羧酸基团和精氨酸残基的修饰可有效抑制海藻糖酶活性。底物海藻糖可保护海藻糖酶不受修饰剂的影响。修饰动力学结果显示,海藻糖酶活性中心可能包含1个羧酸基团和2个精氨酸残基。【结论】结果表明,含有羧基的谷氨酸和天冬氨酸是海藻糖酶活性中心的催化残基,精氨酸是维持海藻糖酶活性的必要残基。本研究结果可为开发新型农药提供理论支持。     

浙江蝮蛇(Agkistrodon halys Pallas)蛇毒激肽释放酶Ⅰ的分离纯化及其性质的研究

浙江产蝮蛇(Agkistrodon halys Pallas)蛇毒中含有激肽释放酶,不需活化即可水解激肽原,释放激肽,并具有较弱的精氨酸酯酶的活力。粗毒经DEAE纤维素(DE-22,DE-52)和Sephadex G-75分离纯化后,可得到两个激肽释放酶的组分:Ⅰ与Ⅱ,二者电泳行为与酶活力有所不同,激肽释放酶Ⅰ在聚丙烯酰胺凝胶电泳中呈一条带,而组分Ⅱ中还杂有少量组分Ⅰ。激肽释放酶Ⅰ为一糖蛋白,含糖量20.3%,约由221个氨基酸残基组成,凝胶过滤和SDS电泳测定其分子量分别为31,000和30,000。此酶具有严格的底物专一性,能作用于激肽释放肽的专一底物Z-Phe-Arg-MCA及Bz-Pro-Phe-Arg-PA,不作用于一般蛋白质底物酪蛋白,对TAME的水解速度仅是对BAEE的14%。以BAEE为底物时,其最适pH为8～9,K_m值为2.85×10~(-4)M。本文测定了不同pH和不同温度下酶的稳定性,pH低于5或大于9,温度在40℃以上,酶活力迅速下降。其精氨酸酯酶及激肽释放酶的活力均能被丝氨酸蛋白酶抑制剂PMSF和DFP所抑制,两者呈平行关系,但都不被胰蛋白酶的专一抑制剂TLCK所抑制,慈菇抑制剂与大豆(Kunitz)抑制剂对此酶有部分抑制作用。经磷酸纤维素等阳离子交换树脂层析或交联的慈菇抑制剂Sepharose-4B亲合层析也能提纯激肽释放酶Ⅰ,但提纯后精氨酸酯酶活力下降,激肽释放活力几乎全部丧失。经圆二色光谱测定表明,酶的构象已发生改变。     

双功能尿苷酰转移/去除酶GlnD在谷氨酸棒杆菌JNR中的功能

【目的】通过改造谷氨酸棒杆菌JNR中双功能尿苷酰转移/去除酶GlnD,减弱尿苷酰去除酶的活性,增强NH_4~+的转运和利用,提高L-精氨酸的合成。【方法】本文对来源于谷氨酸棒杆菌的突变菌株JNR中的双功能尿苷酰转移/去除酶GlnD进行整合突变,采用同源重组的方法将H_(414)和D_(415)位点突变为两个丙氨酸AA,在此菌株的基础上过量表达PII蛋白GlnK,并对其进行尿苷酰化研究,离子色谱检测摇瓶发酵过程中NH4+的浓度,并对最终的改造菌株进行连续流加发酵分析。【结果】该双功能尿苷酰转移/去除酶在谷氨酸棒杆菌中成功进行整合突变,有效减弱了尿苷酰去除酶的活性;同时过表达PII蛋白GlnK,其酰基化程度明显增强。摇瓶发酵结果表明菌株L4消耗NH_4~+增加,L-精氨酸产量为36.2±1.2 g/L,比对照菌株L3高出22.7%。5-L发酵罐实验结果显示改造菌株L4的L-精氨酸的产量为52.2 g/L,较野生型菌株L0提高了25.3%。【结论】谷氨酸棒杆菌合成L-精氨酸的过程中氮源是必不可少的。减弱GlnD尿苷酰去除酶的活性后,胞内尿苷酰化的GlnK-UMP增加,GlnK-UMP与氮转录调控因子AmtR结合,转运至胞内的NH_4~+浓度提高,促使L-精氨酸产量显著提高。     

蛇肌果糖1,6-二磷酸酯酶精氨酸残基的化学修饰

蛇肌果糖1,6-二磷酸酯酶的精氨酸残基被苯乙二醛或2,3-丁二酮修饰后,可导致酶催化活性以及对AMP抑制的敏感性的丧失。在修饰时,有底物或AMP存在,可分别保护酶的这两种性质,表明与活力有关以及与AMP抑制有关的是两类不同的精氨酸残基。在底物保护了与活力有关的精氨酸残基后,可以观察到修饰引起酶对AMP抑制的脱敏,完全脱敏后,每一亚基有2个精氨酸残基被修饰。在本文条件下,K~ 对酶的激活作用以及K~ 存在时酶对AMP抑制敏感性增强等性质均不因精氨酸残基的修饰而变化。     

Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen

Introduction

Members of the peptidylarginine deiminase (PAD) family catalyse the posttranslational conversion of peptidylarginine to peptidylcitrulline. Citrullination of proteins is well described in rheumatoid arthritis (RA), and hypercitrullination of proteins may be related to inflammation in general. PAD activity has been demonstrated in various cell lysates, but so far not in synovial fluid. We aimed to develop an assay for detection of PAD activity, if any, in synovial fluid from RA patients.

Methods

An enzyme-linked immunosorbent assay using human fibrinogen as the immobilized substrate for citrullination and anti-citrullinated fibrinogen antibody as the detecting agent were used for measurement of PAD activity in synovial fluid samples from five RA patients. The concentrations of PAD2 and calcium were also determined.

Results

Approximately 150 times lower levels of recombinant human PAD2 (rhPAD2) than of rhPAD4 were required for citrullination of fibrinogen. PAD activity was detected in four of five synovial fluid samples from RA patients and correlated with PAD2 concentrations in the samples (r = 0.98, P = 0.003). The calcium requirement for half-maximal activities of PAD2 and PAD4 were found in a range from 0.35 to 1.85 mM, and synovial fluid was found to contain sufficient calcium levels for the citrullination process to occur.

Conclusions

We present an assay with high specificity for PAD2 activity and show that citrullination of fibrinogen can occur in cell-free synovial fluid from RA patients.     

Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors

Protein Arginine Deiminase 4 (PAD4) has emerged as a leading target for the development of a Rheumatoid Arthritis (RA) pharmaceutical. Herein, we describe the development of a novel screen for PAD4 inhibitors that is based on a PAD4-targeted Activity-Based Protein Profiling reagent, denoted Rhodamine-conjugated F-Amidine (RFA). This screen was validated by screening 10 Disease Modifying Anti-Rheumatic Drugs (DMARDs) and identified streptomycin, minocycline, and chlortetracycline as micromolar inhibitors of PAD4 activity.     

Protein arginine deiminase 4: evidence for a reverse protonation mechanism

The presumed role of an overactive protein arginine deiminase 4 (PAD4) in the pathophysiology of rheumatoid arthritis (RA) suggests that PAD4 inhibitors could be used to treat an underlying cause of RA, potentially offering a mechanism to stop further disease progression. Thus, the development of such inhibitors is of paramount importance. Toward the goal of developing such inhibitors, we initiated efforts to characterize the catalytic mechanism of PAD4 and thereby identify important mechanistic features that can be exploited for inhibitor development. Herein we report the results of mutagenesis studies as well as our efforts to characterize the initial steps of the PAD4 reaction, in particular, the protonation status of Cys645 and His471 prior to substrate binding. The results indicate that Cys645, the active site nucleophile, exists as the thiolate in the active form of the free enzyme. pH studies on PAD4 further suggest that this enzyme utilizes a reverse protonation mechanism.     

Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors

Protein arginin deaminase 4 (PAD4) is a calcium dependent enzyme which catalyses the conversion of peptidyl-arginine into peptidyl-citrulline and is implicated in several diseases such as rheumatoid arthritis (RA) and cancer. Herein we report the discovery of novel small-molecule, non peptidic PAD4 inhibitors incorporating primary/secondary guanidine moieties.     

PAD4 is not essential for disease in the K/BxN murine autoantibody-mediated model of arthritis

Introduction

Both murine and human genome-wide association studies have implicated peptidyl arginine deiminase (PAD4) as a susceptibility gene in rheumatoid arthritis (RA). In addition, patients with RA commonly have autoantibodies which recognize PAD4 or and/or citrullinated peptides. This study aims to evaluate the role of PAD4 in the effector phase of arthritis.

Methods

PAD4 knock out (KO) and wild type (WT) C57BL/6J mice were injected with K/BxN sera to induce disease. Progression of disease was monitored by measuring paw and ankle swelling and clinical indexes of disease, and pathogenesis was assessed by indexing of clinical progression on paws collected from WT and PAD4 KO mice injected with K/BxN serum. PAD4 activity was determined by visualization of neutrophil extracellular traps (NETs) and immunohistological analysis of histone citrullination.

Results

PAD4 activity is readily detectable in the inflamed synovium of WT but not PAD4 deficient animals, as demonstrated by histone citrullination and NET formation. However, PAD4 WT and KO animals develop K/BxN serum transfer disease with comparable severity and kinetics, with no statistically significant differences noted in clinical scores, swelling, joint erosion or joint invasion.

Conclusions

PAD4 WT and KO mice develop disease in the K/BxN serum transfer model of arthritis with similar severity and kinetics, indicating that PAD4 is dispensable in this effector phase model of disease.     

Local administration of glucocorticoids decreases synovial citrullination in rheumatoid arthritis

Introduction

Protein citrullination is present in the rheumatoid synovium, presumably contributing to the perpetuation of chronic inflammation, in the presence of specific autoimmunity. As a result, the present study examined the possibility that effective antirheumatic treatment will decrease the level of synovial citrullination.

Methods

Synovial biopsies were obtained from 11 rheumatoid arthritis (RA) patients before and after 8 weeks of treatment with 20 mg methotrexate weekly, 15 RA patients before and 2 weeks after an intraarticular glucocorticoid injection, and eight healthy volunteers. Synovial inflammation was assessed with double-blind semiquantitative analysis of lining thickness, cell infiltration, and vascularity by using a 4-point scale. Expression of citrullinated proteins (CPs) with the monoclonal antibody F95 and peptidylarginine deiminase (PAD) 2 and 4 was assessed immunohistochemically with double-blind semiquantitative analysis. In vitro synovial fluid (SF), peripheral blood (PB), mononuclear cells (MCs), and synovial explants obtained from RA patients were incubated with dexamethasone and analyzed with immunohistochemistry for expression of CP as well as PAD2 and PAD4 enzymes.

Results

The presence of synovial CP was almost exclusive in RA compared with healthy synovium and correlated with the degree of local inflammation. Treatment with glucocorticoids but not methotrexate alters expression of synovial CP and PAD enzymes, in parallel with a decrease of synovial inflammation. Ex vivo and in vitro studies suggest also a direct effect of glucocorticoids on citrullination, as demonstrated by the decrease in the level of citrullination and PAD expression after incubation of SFMC and synovial explants with dexamethasone.

Conclusion

Synovial citrullination and PAD expression are dependent on local inflammation and targeted by glucocorticoids.     

Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility

Introduction

Neutrophil extracellular traps (NETs) have recently been implicated in a number of autoimmune conditions, including rheumatoid arthritis (RA). We examined the underlying signaling pathways triggering enhanced NETosis in RA and ascertained whether the products of NETosis had diagnostic implications or usefulness.

Methods

Neutrophils were isolated from RA patients with active disease and from controls. Spontaneous NET formation from RA and control neutrophils was assessed in vitro with microscopy and enzyme-linked immunosorbent assay (ELISA) for NETosis-derived products. The analysis of the signal-transduction cascade included reactive oxygen species (ROS) production, myeloperoxidase (MPO), neutrophil elastase (NE), peptidyl arginine deiminase 4 (PAD4), and citrullinated histone 3 (citH3). NET formation was studied in response to serum and synovial fluid and immunoglobulin G (IgG) depleted and reconstituted serum. Serum was analyzed for NETosis-derived products, for which receiver operator characteristic (ROC) curves were calculated.

Results

Neutrophils from RA cases exhibited increased spontaneous NET formation in vitro, associated with elevated ROS production, enhanced NE and MPO expression, nuclear translocation of PAD4, PAD4-mediated citrullination of H3, and altered nuclear morphology. NET formation in both anti-citrullinated peptide antibody (ACPA)-positive and -negative RA was abolished by IgG depletion, but restored only with ACPA-positive IgG. NETosis-derived products in RA serum demonstrated diagnostic potential, the ROC area under the curve for cell-free nucleosomes being >97%, with a sensitivity of 91% and a specificity of 92%. No significant difference was observed between ACPA-positive and -negative cases.

Conclusions

Signaling elements associated with the extrusion of NETs are significantly enhanced to promote NETosis in RA compared with healthy controls. NETosis depended on the presence of ACPA in ACPA-positive RA serum. The quantitation of NETosis-derived products, such as cell-free nucleosomes in serum, may be a useful complementary tool to discriminate between healthy controls and RA cases.